Dr. Bhawna Sirohi has called for a national five-year policy to make precision cancer care, including genomic testing, part of public health schemes. This move aims to standardize advanced cancer treatments in India. For investors, this signals a potential increase in demand for diagnostic testing and targeted therapies, though the success depends on how the government integrates these expensive services into insurance frameworks like Ayushman Bharat.
Precision oncology—the practice of tailoring cancer treatment to a patient's specific genetic profile—is emerging as a focal point for India’s healthcare sector. Dr. Bhawna Sirohi, medical director at the Vedanta Medical Research Foundation-BALCO Medical Centre, has proposed a five-year national policy to integrate genomic testing and targeted therapies into public health schemes. This recommendation highlights a structural shift in how India manages cancer, moving away from broad-spectrum chemotherapy toward more precise, DNA-based interventions.
The Shift in Diagnostic and Pharma Demand
The move toward precision care directly affects two major areas of the healthcare market: diagnostic laboratories and pharmaceutical companies. Large diagnostic chains have been investing in Next-Generation Sequencing (NGS) capabilities to identify specific gene mutations. If genomic testing is formally included in public health schemes like Ayushman Bharat, diagnostic companies could see a significant increase in test volumes. However, investors often watch whether these services will be provided at capped prices, which could influence profit margins.
On the pharmaceutical side, the industry is gradually shifting focus from conventional chemotherapy drugs to targeted therapies and biosimilars. While targeted drugs often carry higher price tags, their adoption is growing as evidence of better patient outcomes increases. A national policy that encourages these treatments could help companies expand their market share, but it also places pressure on them to improve cost-efficiency to ensure the treatments remain accessible.
Challenges to Implementation
While the proposal aims to increase access, several operational hurdles remain. Precision oncology requires a highly skilled workforce, including molecular pathologists, geneticists, and bioinformaticians. Current capacity in India remains concentrated in major urban centers. Expanding this reach to rural areas, as noted in recent efforts by state governments like Chhattisgarh to map disease burdens, presents a significant logistics and infrastructure challenge.
Financial viability is another key monitorable. While the government-backed DIAMOnDS project is currently scaling diagnostic capabilities for specific cancers, the long-term sustainability of covering expensive targeted drugs through public schemes depends on government budget allocations and drug pricing regulations. Investors should also note that rural or tribal regions face difficulties beyond just medical availability, such as travel costs and lack of specialized daycare facilities, which could affect the actual utilization of any new infrastructure.
What Investors Should Track
Moving forward, the primary monitorables for the sector include updates on the integration of genomic testing into national health insurance frameworks and any subsequent changes in reimbursement rates. Investors may also look for data on the utilization of existing testing infrastructure and how pharmaceutical companies adjust their oncology product portfolios to meet potential public health demand. The speed at which skilled medical talent is trained and the ability of diagnostic labs to maintain profitability while handling higher testing volumes will be critical factors in the coming years.